TFF Pharmaceuticals — IPO Roadshow (August 2019)
35 slides from TFF Pharmaceuticals's IPO roadshow presentation, Aug 23, 2019
Slide 1: Corporate Presentation 2019: Advanced Technology for Better Drug Delivery Options
Corporate Presentation 2019 Advanced Technology for Better Drug Delivery Options
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT 2 SPECIAL NOTE REGARDING FORWARD - LOOKING STATEMENTS This document contains forward - looking statements concerning TFF Pharmaceuticals, Inc. (“TFF”, the “Company,” “we,” “us,” and “o ur”). The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,
Slide 3: Company Overview
COMPANY OVERVIEW • The Thin Film Freezing platform converts poorly absorbed drugs into inhalable dry powder drugs in multiple $Billion markets • Expect two NDA filings within 34 months at clinical and development cost of $27MM • CEO Glenn Mattes is an experienced pharma industry executive (Centocor,
Slide 4: TFF Leadership and Board of Directors
PREVIOUS EXPERIENCE TFF LEADERSHIP BOARD OF DIRECTORS Highly Experienced Healthcare Executives • Former CEO and Board level roles • Deep functional experience in all areas of healthcare companies • Commercially successful enterprises • Track record of numerous significant exits and transactions 4 GL
Slide 5: Problem: Poorly Absorbed Drugs
PROBLEM 5 Poorly Absorbed Drugs Missing the Target: Many drugs intended for one organ, especially therapeutics intended for lung conditions, often don’t reach their target due to poor absorption. This can cause poor efficacy and serious safety concerns. This is true not only for lung conditions but
Slide 6: Thin Film Freezing platform for enabling inhalable drugs
Industry - validated, peer - reviewed and scalable platform • Platform has been tested in a clinical setting • More than a dozen finished formulations of high value drugs, both small molecules & biologics • TFF is manufacturing drugs for clinical studies using GMP standards • Strong IP portfolio: TF
Slide 7: Two NDA filings expected within months
Two NDA filings expected within 34 months Initial NDA Filing (TFF VORI) • Expected in 31 months via 505(b)(2) pathway Second NDA Filing (TFF TAC) • Expected in 34 months via 505(b)(2) pathway TFF Triple Combo • Targets COPD; Pursuing Big Pharma Collaboration Business Development • Broad array of TFF
Slide 8: Multiple Large Target Market Opportunities
MULTIPLE LARGE TARGET MARKET OPPORTUNITIES 8 • COPD market $10B annually (2015) going to $14B (2025) 3 TRIPLE COMBO TFF VORI • Antifungal sales topped $4B 1 • Global immunosuppressant market for acute rejection $15B 2 annually by 2023 TFF TAC • Dozens of off - patent drug targets, many addressing ma
Slide 9: Thin Film Freezing process steps
9 COMMERCIALIZED PRODUCT POWDER FILLING IN CAPSULE SOLVENT REMOVAL BY LYOPHILIZATION RAPID - FREEZING ON A CRYOGENIC DRUM DRUG/EXCIPIENT IN SOLUTION
Slide 10: TFF Platform Advantages
TFF PLATFORM ADVANTAGES 10 POTENTIAL TO PREVENT MOLECULAR DAMAGE: SUITABILITY FOR DRY POWDER INHALERS: YES NO YES YES YES YES YES NO YES NO NO YES
Slide 11: GMP Manufacturing Readiness
• TFF has engaged Core Rx and Irisys to manufacture GMP batches of VORI and TAC for clinical trials and is in discussions with Patheon for a long - term commercial manufacturing agreement • TFF process scale supports Phase I/II supply needs and business development • Supplies for 28 - day GLP studie
Slide 12: TFF Business Model: Two-Pronged Strategy
12 A TWO - PRONGED STRATEGY FOR LEVERAGING TFF FORMULATIONS AND MAXIMIZING VALUE IN - HOUSE DEVELOPMENT • TFF VORI for ABPA/IPA • TFF TAC for lung transplant and severe asthma • Additional pipeline assets in early development, one provisional patent already filed PHARMA LICENSING PLATFORM • Pursue R
Slide 13: Voriconazole Inhalation Powder Target Indications
Voriconazole Inhalation Target Indications: Voriconazole Inhalation Powder is an azole antifungal being developed for the treatment of adults and pediatric patients 2 years of age and older with: • Invasive Pulmonary Aspergillosis (IPA) • Allergic Bronchopulmonary Aspergillosis (ABPA) 13 VORICON
Slide 14: TFF VORI: Well tolerated, 3X better survival in pre-clinical testing
• Advantages over alternatives: Reduced side effects; direct to site of infection • Alternatives: Oral and IV Amphotericin, Voriconazole and other Azoles, Candins • Markets: • Antifungal sales topped $4B 1 . However, an inhaled voriconazole for ABPA and unmet medical needs could achieve blockbuster
Slide 15: Tacrolimus Inhalation Powder Target Indication
Tacrolimus Inhalation Powder Target Indication: Either alone or in combination, Tacrolimus Inhalation Powder is being developed for the prophylaxis of organ rejection in patients receiving lung transplants. 15 TACROLIMUS INHALATION POWDER TARGET INDICATION
Slide 16: TFF TAC: Already shown to be safe in healthy humans
• Advantages over alternatives: Reduced side effects; direct to site • Alternatives: Oral and IV immunosuppressants • Markets: • Lung Transplant addressable market: >$1B 5 * • Severe Asthma >$1B 6 annually, growing to $5.3B 6 by 2023 • Safety: • Rat: well tolerated 28 days, high dose tolerance • Wel
Slide 17: TFF VORI and TFF TAC Sales Worldwide
TFF VORI AND TFF TAC SALES WORLDWIDE 17 TFF VORI* • $160MM in potential net peak sales worldwide • Assuming acute IPA penetration of 18%; at risk penetration 2% TFF TAC* • $400MM in potential net peak sales worldwide • Assuming 27% penetration MARKET ACCESS CONSIDERATION Once TFF VORI and TFF TAC de
Slide 18: Business Development: The Power of TFF Platform
18 BUSINESS DEVELOPMENT – The Power of TFF Platform • Pursuing R&D Collaborations to provide direct - to - lung delivery for oncology, COPD, PAH, CF, biologics, combinations, and others • Enhance large pharma’s life cycle on already marketed drugs – 18 potential candidates already identified • Compe
Slide 19: Pharma Target Partners
PHARMA TARGET PARTNERS 19 Active discussions continuing with the following pharma targets on potential collaborations: Ongoing discussions with the following pharma partners:
Slide 20: CBD Target Partners
CBD TARGET PARTNERS 20 Active discussions continuing with the following medicinal and/or Rx partners on potential collaborations: Ongoing discussions with the following medicinal and/or Rx partners:
Slide 21: Internal Potential Programs Under Consideration
INTERNAL POTENTIAL PROGRAMS 21 UNDER CONSIDERATION FOR POTENTIAL DEVELOPMENT BY TFF Existing known compounds already delivered to the lung Currently Evaluating: • PAH Potential Others: • COPD treatments • CF treatments • Respiratory distress syndrome Existing known compounds non - lung delivered Cur
Slide 22: VORI and TAC Inflection Points/Catalytic Events
VORI AND TAC - INFLECTION POINTS/CATALYTIC EVENTS 22
Slide 23: Use of Proceeds
USE OF PROCEEDS 23 • Pre - clinical development, analysis & preparation; completion of Phase I and Phase II studies • Invest selectively in potential expansion products • Highly selective expansion of TFF core team • Continue and expand business development opportunities • Continue manufacturing of
Slide 24: Offering Details
OFFERING DETAILS 24 Proposed Offering With Over - allotment Option Proposed Price per Share $5.00 $5.00 Shares Offered 4.4 million 5.1 million Gross Proceeds $22 million $25.3 million Shares Outstanding Post - Offering 17.9 million 18.6 million Implied Market Cap Post - Offering (at $5 per share) $8
Slide 25: Key Takeaways
• Revolutionary platform for enabling inhalable drugs • Multiple $Billion+ markets • GMP manufacturing established for clinical trials with leading CMO partners • Accelerated 505(b)(2) regulatory pathway • Two NDA filings for approximately $27MM clinical cost • Broad array of business development in
Slide 26: Endnotes
ENDNOTES 26 1. Antifungal Market Growth - 2013. Global Data Research Report https://www.globaldata.com/ (last accessed February 15, 2019). TFF Pharmaceuticals Estimates Q1 2019 2. Growth of Global Immunosuppressant Market for Acute Rejection - 2013. Global Data Research Report https://www.globaldata
Slide 27: TFF Pharmaceuticals Thank You
TFF PHARMACEUTICALS THANK YOU
Slide 28: TFF Executive Team
TFF EXECUTIVE TEAM • 30 years of business leadership experience in development and commercial launches of global therapeutics • Former CEO of publicly traded Arno Therapeutics, and senior positions with Tibotec Therapeutics, a J&J operating company, and Rhone - Poulenc Rorer • Critical roles in laun
Slide 29: Board Members
HARLAN F. WEISMAN, M.D. BOARD MEMBER • Senior healthcare executive with 30 years experience in the launch of pharmaceutical products • Currently Managing Director of And - One Consulting, LLC, advising medical product companies, investment firms, and government and non - government healthcare organi
Slide 30: TFF VORI: Clinical Development Plans
TFF VORI: CLINICAL DEVELOPMENT PLANS Clinical Trial Plans Phase I – SAD/MAD Trial in normal healthy volunteers • Endpoints: Safety, tolerability and pharmacokinetics • Single Ascending Dose (SAD) • 4 cohorts with 6 active + 2 Placebo (6 + 2 design) • 10, 20, 40, and 80 mg dose levels • Multiple Asce
Slide 31: TFF VORI Development Timeline
Total Amount: Approximately $11MM TFF VORI DEVELOPMENT TIMELINE Additional scenarios exist that include the possibility of longer durations, costs, efforts, and/or even FDA denying use of 5 05 (B)(2) application, although TFF believes the above timeline to be reasonable and most relevant based on cu
Slide 32: TFF TAC: Clinical Development Plans
TFF TAC: CLINICAL DEVELOPMENT PLANS Clinical Trial Plans Phase I – SAD/MAD Trial in normal healthy volunteers • Endpoints: Safety, tolerability and pharmacokinetics • Single Ascending Dose (SAD) • 4 cohorts with 6 active + 2 Placebo (6 + 2 design) • 0.5, 1.0, 2.5 and 5.0 mg dose levels • 2.5 mg coho
Slide 33: TFF TAC Development Timeline
Total Amount: Approximately $15MM TFF TAC DEVELOPMENT TIMELINE A6 Additional scenarios exist that include the possibility of longer durations, costs, efforts, and/or even FDA denying use of 5 05 (B)(2) application, although TFF believes the above timeline to be reasonable and most relevant based on
Slide 34: Transformation Since Series A
TRANSFORMATION SINCE SERIES A • Completed / completing pre - clinical toxicology programs in support of VORI and TAC IND filings • Secured GMP site manufacturing support for VORI and TAC phase I & II campaigns • Technical assessment of TFF enabling technology on CBD and vaccine portfolio extensions
Slide 35: Scientific founder profile (Dr. Williams)
Dr. Williams’ research interests include development of novel drug delivery systems for oral, pulmonary, nasal, injectable, buccal and topical administration, as well as the development of novel particle engineering technologies. His research devotes significant effort to enhance drug solubility and